- Home
- EQBK vs SCLXW Comparison
EQBK vs SCLXW Comparison
Compare EQBK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- SCLXW
- Stock Information
- Founded
- EQBK 2002
- SCLXW N/A
- Country
- EQBK United States
- SCLXW United States
- Employees
- EQBK N/A
- SCLXW 117
- Industry
- EQBK Major Banks
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- EQBK Finance
- SCLXW Health Care
- Exchange
- EQBK Nasdaq
- SCLXW Nasdaq
- Market Cap
- EQBK N/A
- SCLXW N/A
- IPO Year
- EQBK 2015
- SCLXW N/A
- Fundamental
- Price
- EQBK $39.55
- SCLXW $0.10
- Analyst Decision
- EQBK Hold
- SCLXW
- Analyst Count
- EQBK 5
- SCLXW 0
- Target Price
- EQBK $45.60
- SCLXW N/A
- AVG Volume (30 Days)
- EQBK 74.5K
- SCLXW 4.0K
- Earning Date
- EQBK 04-15-2025
- SCLXW 03-07-2025
- Dividend Yield
- EQBK 1.52%
- SCLXW N/A
- EPS Growth
- EQBK 700.00
- SCLXW N/A
- EPS
- EQBK 4.00
- SCLXW N/A
- Revenue
- EQBK $220,373,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- EQBK $8.23
- SCLXW N/A
- Revenue Next Year
- EQBK $6.39
- SCLXW N/A
- P/E Ratio
- EQBK $9.89
- SCLXW N/A
- Revenue Growth
- EQBK 59.55
- SCLXW 22.02
- 52 Week Low
- EQBK $30.44
- SCLXW $0.18
- 52 Week High
- EQBK $50.85
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- EQBK 42.32
- SCLXW N/A
- Support Level
- EQBK $38.54
- SCLXW N/A
- Resistance Level
- EQBK $40.87
- SCLXW N/A
- Average True Range (ATR)
- EQBK 0.92
- SCLXW 0.00
- MACD
- EQBK 0.06
- SCLXW 0.00
- Stochastic Oscillator
- EQBK 42.62
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.